← Enanta Pharmaceuticals, Inc. (ENTA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Enanta Pharmaceuticals, Inc. (ENTA)
Pharmaceutical Preparations · market cap $350M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-16 (est.)
Earnings
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Enanta Pharmaceuticals (ENTA) is a small-cap pharma with 120 employees and a $415M market cap, running a pipeline of Phase 2 assets across RSV (EDP-938, EDP-323), COVID-19 (EDP-235), primary biliary cholangitis (EDP-305), and NASH (EDP-305). The company carries only $34.9M in cash against a burn rate that implies roughly 5.6 months of runway, creating acute near-term financing pressure ahead of any Phase 2 readouts.
The catalyst path
- 2026-11-16 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EDP-938 | Phase 2 | Respiratory Syncytial Virus |
| EDP-938 Dose 1 | Phase 2 | RSV Infection |
| EDP-235 | Phase 2 | COVID-19 |
| EDP-305 1 mg | Phase 2 | Primary Biliary Cholangitis |
| EDP-305 Dose 1 | Phase 2 | Non-Alcoholic Steatohepatitis |
| EDP-323 Dose Regimen 1 | Phase 2 | RSV Infection |
Price & technical context
3-month
-15.0%
6-month
-1.0%
12-month
+7.3%
52-wk range
$10.33–$16.85
vs 50-day MA
-2.0%
vs 200-day MA
-4.9%
Realized vol
48.7%
Max drawdown
-67.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ENTA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.